Diego Gutiérrez, I3A researcher, among the 100 most influential scientists of the decade in Computer Graphics
19 May 2021
They discover a mutation that can help better understand breast cancer
19 May 2021
Preliminary results from the 'CombiVacs' clinical trial have shown that one dose of the Pfizer vaccine produces a strong immune response and mild to moderate side effects in these people.
The preliminary results of the 'CombiVacs' clinical trial, launched by the Carlos III Health Institute (ISCIII), have shown that one dose of the Pfizer covid-19 vaccine produces a strong immune response and mild to moderate side effects. in people under 60 years of age who received a single dose of Astrazeneca.
At the beginning of April, Health made the decision to vaccinate with Astrazeneca only those over 60 years of age due to the appearance of "very rare" thrombotic events, especially in younger people, following the example of other European countries such as France or Germany.
This restriction caused many people under 60 years of age who had already received a dose of Astrazeneca could not receive the mandatory second injection. Those affected are mainly essential personnel such as teachers or police officers.
The test has been carried out in five Spanish hospitals: La Paz in Madrid, the San Carlos Clinic in Madrid, the Vall d'Hebron in Barcelona, the Barcelona Clinic and the Cruces de Vizcaya. The National Center for Microbiology, for its part, has also participated as the central analysis laboratory of the study.
In this phase 2, comparative, randomized and adaptive clinical trial, 676 patients from different age groups and regions from Spain who have received a single dose of Astrazeneca, and range from 18 to 59 years old.
They have been divided into two groups: one of 226 who received the dose "immediately" and another of 450 who received it after 28 days. The results presented this Tuesday are those analyzed 14 days after receiving the Pfizer dose.
The decision, this afternoon
The final decision will be made this afternoon in the Public Health Commission, which will meet with the objective of decide how you will immunize people under 60 years of age that they received a first dose of Astrazeneca and that they should begin to complete their regimen next week, something that could be done with the Pfizer serum.
The general directors of the communities and the Ministry will now have on the table the preliminary results of this CombiVacs study, but also the preliminary findings of another study published last week in the magazine 'The Lancet', in which experts from the University of Oxford point out that alternating doses of different vaccines against covid-19 causes more frequent mild and moderate reactions than with two injections of the same preparation.
With all the evidence collected to date, technicians will try to finally give an answer to the almost two million Spaniards Those under 60 years of age vaccinated in the first instance with Vaxzevria (trade name of Astrazeneca), who today do not know how they are going to complete their regimen.
On April 30, they agreed to extend the interval between doses for this group to 16 weeks - not for those over 60 - although what is recommended by the European Medicines Agency (EMA) is that the 12-week schedule be respected, which is also what is contemplated in the drug's own leaflet.
